WhiteOak Capital Pharma and Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹17.68+0.72%
07 Sept 2026
1 Week returns: -0.85 %
Category rank: 9/23
1 Month returns: 1.21 %
Category rank: 6/23
1 Year CAGR: 22.99 %
Category rank: 6/21
3 Years CAGR: -
Category rank: -
5 Years CAGR: -
Category rank: -
Key Talking Points
Important talking points about the scheme's performance, expense ratio and other factors — grouped by positive, negative, and neutral stance.
Positive
Relatively low expense ratio
Expense ratio of the scheme (1.1%) is lower than average expense ratio of the category (1.66%), excluding index funds and ETFs
This measures the relative expense of the scheme with respect to average expense ratio of the category. Investors should always prefer schemes with lower expense, everything else remaining the same
What is Expense ratio?
Negative
Not enough talking points with negative stance
Neutral
Not enough performance data
Since this is a relatively new scheme (less than 3 years), we do not have sufficient data to conduct meaningful performance analysis
Scheme Overview
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
Plan Variants
No variants available.
Fund Managers
Key Scheme Details
Inception
7 Feb 2024
Expense Ratio
1.1%
AUM
₹824.9 Cr
Lock in
No lock in
Taxation
Equity
Min. Investment
₹500
Min. Addl Investment
-
Min. SIP Investment
₹100
Exit load
-
AMC Overview
WhiteOak Capital Mutual Fund background and AUM insights, category-wise distribution and historical AUM growth.
AMC Details
AMC
WhiteOak Capital Mutual Fund
CEO
Aashish P Somaiyaa(Chief Executive Officer)
CIO
Ramesh Mantri(Chief Investment Officer)
IRO
Anup Mehta
Trustee
WhiteOak Capital Trustee Limited
Phone
Website
Address
Unit No. B4, 6th Floor,, Cnergy, Appasaheb Marathe Marg,, Prabhadevi, Mumbai
Frequently Asked Questions
What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is ₹17.68 as of 6 Sep 2026. The NAV of a mutual fund reflects the per-unit market value of the fund's holdings and is updated at the end of every trading day.
What is the AUM of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The AUM (Assets Under Management) of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is ₹824.9 crore. AUM represents the total market value of assets the fund currently manages on behalf of its investors.
What is the expense ratio of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The expense ratio of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is 1.10% per annum. This is the annual fee charged by the fund house to manage your investment. A lower expense ratio means more of your returns stay with you — which is one reason direct plans have a lower expense ratio than regular plans.
Who is the fund manager of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is managed by Piyush Baranwal, Ashish Agrawal, Ramesh Mantri, Trupti Agrawal, Dheeresh Pathak. You can check the full list of fund managers in the "Fund Manager" section above.
What is the benchmark of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The benchmark of WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is BSE Healthcare Total Return Index. This is the index against which the fund's performance is measured. Consistently beating the benchmark over long periods is a key indicator of a fund manager's skill.
When was WhiteOak Capital Pharma and Healthcare Fund Direct-Growth launched?
WhiteOak Capital Pharma and Healthcare Fund Direct-Growth was launched on 7 Feb 2024. The fund has been in existence for 2 years. A longer track record gives investors more data to evaluate how the fund has performed across different market cycles.
What is the minimum investment in WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The minimum investment in WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is ₹500 for a lump sum and ₹100 per month for a SIP (Systematic Investment Plan). SIPs allow you to invest a fixed amount regularly, making it easier to build wealth over time without needing a large upfront amount.
What is the exit load on WhiteOak Capital Pharma and Healthcare Fund Direct-Growth?
The exit load on WhiteOak Capital Pharma and Healthcare Fund Direct-Growth is shown in the Scheme Overview section above. Exit load is charged to discourage early withdrawals and protect long-term investors in the fund.
What category does WhiteOak Capital Pharma and Healthcare Fund Direct-Growth belong to?
WhiteOak Capital Pharma and Healthcare Fund Direct-Growth belongs to the Equity: Sectoral-Pharma category. You can view other funds in this category.